Guilford, CT – June 26, 2018 Ce3 Inc., a Connecticut based CRO, has announced it is consolidating its data and biostatistics unit (Cd3, Inc.) into the Ce3 organization to form a single business unit effective July 1, 2018. Cd3 Inc. had been providing data management and biostatistics services as an affiliated company since its inception in 2008. Over the past 12 months, Ce3’s management has worked closely with Cd3 to optimize integration and delivery of services between the two companies. The consolidation represents the final step of this process. The new management structure will maximize efficiencies and further refine Ce3’s service offerings.

As part of the consolidation, Ce3 is also rebranding under a new logo:

ce3 logo


Industry colleagues and customers will start to see the new logo being rolled out in July of this year in various advertisements, as well as at industry meetings.


About Ce3, Inc.

Ce3, Inc. is a full service CRO focused on providing early phase clinical development services to the biotechnology industry. The company’s therapeutic focus is oncology, and it is actively conducting trials with many emerging therapies and technologies in this area. Since its inception in 2005, Ce3 has concentrated on thoroughly understanding the needs of biotechnology companies, and providing high quality cost effective solutions to support their clients’ regulatory and investor goals.


Company Contact:
Susan Albert
Executive Director

Ce3 has Joined Catalyst Clinical Research to create a market-leading next-generation CRO.